Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 23;7(6):102184.
doi: 10.1016/j.rpth.2023.102184. eCollection 2023 Aug.

Overuse and underuse of thromboprophylaxis in medical inpatients

Barbara Kocher  1 , Pauline Darbellay Farhoumand  2 , Damiana Pulver  1 , Basil Kopp  1 , Damien Choffat  3 , Tobias Tritschler  1   4 , Peter Vollenweider  3 , Jean-Luc Reny  2 , Nicolas Rodondi  1   5 , Drahomir Aujesky  1 , Marie Méan  3 , Christine Baumgartner  1
Affiliations

Overuse and underuse of thromboprophylaxis in medical inpatients

Barbara Kocher et al. Res Pract Thromb Haemost. .

Abstract

Background: Thromboprophylaxis (TPX) prescription is recommended in medical inpatients categorized as high risk of venous thromboembolism (VTE) by validated risk assessment models (RAMs), but how various RAMs differ in categorizing patients in risk groups, and whether the choice of RAM influences estimates of appropriate TPX use is unknown.

Objectives: To determine the proportion of medical inpatients categorized as high or low risk according to validated RAMs, and to investigate the appropriateness of TPX prescription.

Methods: This is a prospective cohort study of acutely ill medical inpatients from 3 Swiss university hospitals. Participants were categorized as high or low risk of VTE by validated RAMs (ie, the Padua, the International Medical Prevention Registry on Venous Thromboembolism, simplified, and original Geneva scores). We assessed prescription of any TPX at baseline. We considered TPX prescription in high-risk and no TPX prescription in low-risk patients as appropriate.

Results: Among 1352 medical inpatients, the proportion categorized as high risk ranged from 29.8% with the International Medical Prevention Registry on Venous Thromboembolism score to 66.1% with the original Geneva score. Overall, 24.6% were consistently categorized as high risk, and 26.3% as low risk by all 4 RAMs. Depending on the RAM used, TPX prescription was appropriate in 58.7% to 63.3% of high-risk (ie, 36.7%-41.3% underuse) and 52.4% to 62.8% of low-risk patients (ie, 37.2%-47.6% overuse).

Conclusion: The proportion of medical inpatients considered as high or low VTE risk varied widely according to different RAMs. Only half of patients were consistently categorized in the same risk group by all RAMs. While TPX remains underused in high-risk patients, overuse in low-risk patients is even more pronounced.

Keywords: hospitalization; prescriptions; prevention; prophylaxis; risk assessment; venous thromboembolism; venous thrombosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prescription and type of thromboprophylaxis in medical inpatients at baseline and at any time during hospitalization for at least one day. ∗ Within 72 hours (median 24 hours) of admission. † Defined as liver failure or any other active bleeding disorder, active bleeding, or hemorrhagic transformation of acute ischemic stroke. § Defined as low-molecular-weight heparin, unfractionated heparin, fondaparinux, or direct oral anticoagulants in a prophylactic dose. ‡ Defined as use of lower extremity compression stockings or bandages, or intermittent pneumatic compression devices. TPX, thromboprophylaxis.
Figure 2
Figure 2
Proportion of medical inpatients at high and low venous thromboembolism risk according to validated RAMs and related prescription of TPX. Variables to calculate VTE risk according to each RAM were collected at baseline (ie, within 72 hours [median 24 hours] of admission). IMPROVE, International Medical Prevention Registry on Venous Thromboembolism; RAMs, risk assessment models; TPX, thromboprophylaxis; VTE, venous thromboembolism. ∗ Refers to prescription of mechanical or pharmacologic TPX at baseline. † Refers to prescription of mechanical or pharmacologic TPX anytime during the entire hospitalization for at least one day.
See this image and copyright information in PMC

References

    1. Heit J.A., O’Fallon W.M., Petterson T.M., Lohse C.M., Silverstein M.D., Mohr D.N., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–1248. - PubMed
    1. Heit J.A. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost. 2002;28:3–13. - PubMed
    1. Guyatt G.H.A., Akl E.A., Crowther M., Guttermann D.D., Schünemann H.J. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S–47S. - PMC - PubMed
    1. Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e278S–e325S. - PMC - PubMed
    1. Goldhaber S.Z., Dunn K., MacDougall R.C. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest. 2000;118:1680–1684. - PubMed